Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company"
Stock Split Watch: 3 Growth Stocks That Could Be Next
10:10am, Friday, 07'th Jun 2024
Shares of MercadoLibre, Booking Holdings, and Regeneron have reached prices in the neighborhood of $1,000 or more, making them obvious candidates for stock splits. None of these three companies has ev
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company"
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
03:25pm, Wednesday, 05'th Jun 2024
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).
LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company"
Health Care Stocks Show Relative Strength as S&P 500 Stalls
03:45pm, Tuesday, 04'th Jun 2024
Several stocks are breaking out and trading near all-time highs.
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company"
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company"
